Outlook Aims To Reverse US FDA’s Rejection Of Bevacizumab For AMD

Low On Cash, Rush Is On To Clarify Agency’s Concerns

 
• By Mandy Jackson
  
Close up cropped shot, face of senior woman eye looking straight, into distance.
Outlook will request at Type A meeting with the FDA to discuss the CRL • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip